Silence Therapeutics Plc (SLN) has released an update.
Silence Therapeutics Plc has announced the retirement of Alistair Gray from its Board of Directors, effective May 1, 2024. Gray’s departure marks the end of nearly a decade of service during which the company has made significant strides in RNA interference technology and advanced its product pipeline. The company acknowledges Gray’s contributions as it continues to develop innovative RNA-based therapies for diseases with unmet needs.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.
